Læknablaðið - 01.04.2018, Side 26

186 LÆKNAblaðið 2018/104
Y F I R L I T
1. Chandratre P, Mallen CD, Roddy E, Liddle J, Richardson
J. “You want to get on with the rest of your life”: a qualita-
tive study of health-related quality of life in gout. Clin
Rheumatol 2016; 35: 1197-205.
2. Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M.
Rising burden of gout in the UK but continuing subopt-
imal management: a nationwide population study. Ann
Rheum Dis 2015; 74: 661-7.
3. Roddy E, Choi H. Epidemiology of Gout. Rheum Dis Clin
North Am 2014; 40: 155-75.
4. MacFarlane LA, Kim SC. Gout: a review of nonmodifiable
and modifiable risk factors. Rheum Dis Clin North Am
2014; 40: 581-604.
5. Schlee S, Bollheimer LC, Bertsch T, Sieber CC, Härle P.
Crystal arthritides – gout and calcium pyrophosphate
arthritis. Z Gerontol Geriatr 2017.
6. Richette P, Doherty M, Pascual E, Barskova V, Becce
F, Castañeda-Sanabria J, et al. 2016 updated EULAR
evidence-based recommendations for the management of
gout. Ann Rheum Dis 2017; 76: 29-42.
7. Loeb JN. The influence of temperature on the solubility of
monosodium urate. Arthritis Rheum 1972; 15: 189-192.
8. Pieterse E, Jeremic I, Czegley C, Weidner D, Biermann
MH, Veissi S, et al. Blood-borne phagocytes internalize
urate microaggregates and prevent intravascular NETosis
by urate crystals. Sci Rep 2016; 6: 38229.
9. Macfarlane LA, Kim SC. Gout A Review of Nonmodifiable
and Modifiable Risk Factors Gout Risk factors Race Sex
Genetics Diet. Gout 2014; 40: 581-604.
10. Dennis M, Benos DJ, Editor D, Abboud F, Editor A,
Koopman WJ, et al. PHYSIOLOGY IN MEDICINE : A
SERIES OF ARTICLES LINKING MEDICINE WITH
SCIENCE. Review Pathogenesis of Gout. Ann Intern Med
2005; 143: 499-516.
11. Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia
and gout: new insights into pathogenesis and treatment.
Bull NYU Hosp Jt Dis 2007; 65: 215-21.
12. Zhu Y, Pandya BJ, Choi HK. Comorbidities of Gout and
Hyperuricemia in the US General Population: NHANES
2007-2008. Am J Med 2012; 125: 679-87. e1.
13. Chhana A, Lee G, Dalbeth N. Factors influencing the
crystallization of monosodium urate: a systematic literat-
ure review. BMC Musculoskelet Disord 2015; 16: 296.
14. Dalbeth N, House ME, Aati O, Tan P, Franklin C, Horne
A, et al. Urate crystal deposition in asymptomatic
hyperuricaemia and symptomatic gout: a dual energy CT
study. Ann Rheum Dis 2015; 74: 908-11.
15. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet 2016;
388: 2039-52.
16. Igel TF, Krasnokutsky S, Pillinger MH. Recent advances in
understanding and managing gout. F1000Res 2017; 6: 247.
17. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet 2016;
388: 2039-52.
18. Sulem P, Gudbjartsson DF, Walters GB, Helgadottir HT,
Helgason A, Gudjonsson SA, et al. Identification of low-
frequency variants associated with gout and serum uric
acid levels. Nat Genet 2011; 43: 1127-30.
19. Guo Z, Zhang J, Wang Z, Ang KY, Huang S, Hou Q, et
al. Intestinal Microbiota Distinguish Gout Patients from
Healthy Humans. Sci Rep 2016; 6: 20602.
20. Vieira AT, MacIa L, Galvão I, Martins FS, Canesso MCC,
Amaral FA, et al. A role for gut microbiota and the meta-
bolite-sensing receptor GPR43 in a murine model of gout.
Arthritis Rheumatol 2015; 67: 1646-56.
21. Mitroulis I, Kambas K, Chrysanthopoulou A, Skendros P,
Apostolidou E, Kourtzelis I, et al. Neutrophil extracellular
trap formation is associated with IL-1β and autophagy
related signaling in gout. PLoS One 2011; 6: 1-10.
22. Rada B. Neutrophil Extracellular Traps and Microcrystals.
J Immunol Res 2017; 2017: 2896380.
23. Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a
new staging system? Ann Rheum Dis 2014; 73: 1598-600.
24. Taylor WJ, Fransen J, Jansen TL, Dalbeth N, Schumacher
HR, Brown M, et al. Study for Updated Gout Classification
Criteria: Identification of Features to Classify Gout.
Arthritis Care Res (Hoboken) 2015; 67: 1304-15.
25. Gunnarsson SI, Guðbjartsson T, Geirsson ÁJ. Tilfelli
mánaðarins. Læknablaðið 2008; 11: 755-6.
26. Eggebeen AT. Gout: an update. Am Fam Physician 2007;
76: 801-8.
27. Abhishek AA, B AER, C MD. Gout – a guide for the gener-
al and acute physicians. 2017; 17: 54-9.
28. Wändell P, Carlsson AC, Li X, Gasevic D, Ärnlöv J,
Holzmann MJ, et al. Gout in immigrant groups: a cohort
study in Sweden. Clin Rheumatol 2017; 36: 1091-102.
29. Sattui SE, Singh JA, Gaffo AL. Comorbidities in Patients
with Crystal Diseases and Hyperuricemia. Rheum Dis
Clin North Am 2014; 40: 251-78.
30. Roddy E. Revisiting the pathogenesis of podagra: why
does gout target the foot? J Foot Ankle Res 2011; 4: 13.
31. Keenan RT. Limitations of the Current Standards of Care
for Treating Gout and Crystal Deposition in the Primary
Care Setting: A Review. Clin Ther 2017; 39: 430-41.
32. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout
and prevention: a systematic review of the literature. Curr
Opin Rheumatol 2011; 23: 192-202.
33. Choi HK, Curhan G. Soft drinks, fructose consumption,
and the risk of gout in men: prospective cohort study. BMJ
2008; 336: 309-12.
34. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G.
Purine-rich foods, dairy and protein intake, and the risk of
gout in men. N Engl J Med 2004; 350: 1093-103.
35. Suresh E, Das P. Recent advances in management of gout.
QJM 2012; 105: 407-17.
36. Wallace SL, Robinson H, Masi AT, Decker JL, Mccarty DJ,
Yü T. Preliminary criteria for the classification of the acute
arthritis of primary gout. Arthritis Rheum 1977; 20: 895-
900.
37. Neogi T, Jansen TLTA, Dalbeth N, Fransen J, Schumacher
HR, Berendsen D, et al. 2015 Gout Classification Criteria:
An American College of Rheumatology/European League
Against Rheumatism Collaborative Initiative. Arthritis
Rheumatol 2015; 67: 2557-68.
38. Janssens HJEM, Fransen J, van de Lisdonk EH, van Riel
PLCM, van Weel C, Janssen M. A diagnostic rule for acute
gouty arthritis in primary care without joint fluid analysis.
Arch Intern Med 2010; 170: 1120-6.
39. Vincent ZL, Gamble G, House M, Knight J, Horne A,
Taylor WJ, et al. Predictors of Mortality in People with
Recent-onset Gout: A Prospective Observational Study. J
Rheumatol 2017; 44: 368-73.
40. Taylor TH, Mecchella JN, Larson RJ, Kerin KD, MacKenzie
TA. Initiation of Allopurinol at First Medical Contact for
Acute Attacks of Gout: A Randomized Clinical Trial. Am J
Med 2012; 125: 1126-34.e7.
41. Rees F, Jenkins W, Doherty M. Patients with gout adhere
to curative treatment if informed appropriately: proof-of-
concept observational study. Ann Rheum Dis 2013; 72:
826-30.
42. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL,
van Weel C. Use of oral prednisolone or naproxen for the
treatment of gout arthritis: a double-blind, randomised
equivalence trial. Lancet 2008; 371: 1854-60.
43. Schumacher HR, Boice J a, Daikh DI, Mukhopadhyay S,
Malmstrom K, Ng J, et al. Randomised double blind trial
of etoricoxib and indometacin in treatment of acute gouty
arthritis. BMJ 2002; 324: 1488-92.
44. van Durme CMPG, Wechalekar MD, Buchbinder R,
Schlesinger N, van der Heijde D, Landewé RB.
Non-steroidal anti-inflammatory drugs for acute gout.
Cochrane Database Syst Rev 2014; 9: CD010120.
45. Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F,
Burgos-Vargas R, Li C. Efficacy and Tolerability of
Celecoxib in the Treatment of Acute Gouty Arthritis: A
Randomized Controlled Trial. J Rheumatol 2012; 39: 1859
LP-1866.
46. Rainer TH, Cheng CH, Janssens HJEM, Man CY, Tam LS,
Choi YF, et al. Oral prednisolone in the treatment of acute
gout: A pragmatic, multicenter, double-blind, randomized
trial. Ann Intern Med 2016; 164: 464-71.
47. Waljee AK, Rogers MAM, Lin P, Singal AG, Stein JD,
Marks RM, et al. Short term use of oral corticosteroids
and related harms among adults in the United States:
population based cohort study. BMJ 2017; 357357: 1-8.
48. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R.
Intra-articular glucocorticoids for acute gout. Cochrane
Database Syst Rev 2013; 4: CD009920.
49. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of Action
of Colchicine in the Treatment of Gout. Clin Ther 2014; 36:
1465-79.
50. Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S.
Colchicine: old and new. Am J Med 2015; 128: 461-70.
51. Terkeltaub RA, Furst DE, Bennett K pd., Kook KA,
Crockett RS, Davis MW. High versus low dosing of oral
colchicine for early acute gout flare: Twenty-four-hour
outcome of the first multicenter, randomized, double-
blind, placebo-controlled, parallel-group, dose-comparis-
on colchicine study. Arthritis Rheum 2010; 62: 1060-8.
52. Schlesinger N. Canakinumab in gout. Expert Opin Biol
Ther 2012; 12: 1265-75.
53. Ottaviani S, Moltó A, Ea H-K, Neveu S, Gill G, Brunier L,
et al. Efficacy of anakinra in gouty arthritis: a retrospective
study of 40 cases. Arthritis Res Ther 2013; 15: R123.
54. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J,
Frampton C, et al. Starting dose is a risk factor for allopur-
inol hypersensitivity syndrome: A proposed safe starting
dose of allopurinol. Arthritis Rheum 2012; 64: 2529-36.
55. Bardin T, Chalès G, Pascart T, Flipo RM, Korng Ea H,
Roujeau JC, et al. Risk of cutaneous adverse events with
febuxostat treatment in patients with skin reaction to
allopurinol. A retrospective, hospital-based study of 101
patients with consecutive allopurinol and febuxostat
treatment. Joint Bone Spine 2015; 83: 314-7.
56. Becker MA, Schumacher HR, Wortmann RL, MacDonald
PA, Eustace D, Palo WA, et al. Febuxostat compared with
allopurinol in patients with hyperuricemia and gout. N
Engl J Med 2005; 353: 2450-61.
57. Engel B, Just J, Bleckwenn M, Weckbecker K. Treatment
Options for Gout. Dtsch Arztelb Int 2017; 114: 215-22.
58. Choi HK. A prescription for lifestyle change in patients
with hyper- uricemia and gout. Curr Opin Rheumatol
2010; 22: 165-172.
59. Rai SK, Fung TT, Lu N, Keller SF, Curhan GC, Choi HK.
The Dietary Approaches to Stop Hypertension (DASH)
diet, Western diet, and risk of gout in men: prospective
cohort study. BMJ 2017; 357: j1794.
60. Fam AG. Gout, diet, and the insulin resistance syndrome.
J Rheumatol 2002; 29: 1350 LP-1355.
61. Levy M, Thaiss CA, Elinav E. Taming the inflammasome.
Nat Med 2015; 21: 213-5.
62. Kuo C-F, Grainge MJ, Zhang W, Doherty M. Global
epidemiology of gout: prevalence, incidence and risk
factors. Nat Rev Rheumatol 2015; 11: 649-62.
Heimildir